Abstract
Inhibition of cyclin-dependent kinase 1 (CDK1) by phosphorylation is a key regulatory mechanism for both the unperturbed cell cycle and the DNA damage checkpoint. Although both WEE1 and MYT1 can phosphorylate CDK1, little is known about the contribution of MYT1. We found that in contrast to WEE1, MYT1 was not important for the normal cell cycle or checkpoint activation. Time-lapse microscopy indicated that MYT1 did, however, have a rate-determining role during checkpoint recovery. Depletion of MYT1 induced precocious mitotic entry when the checkpoint was abrogated with inhibitors of either CHK1 or WEE1, indicating that MYT1 contributes to checkpoint recovery independently of WEE1. The acceleration of checkpoint recovery in MYT1-depleted cells was due to a lowering of threshold for CDK1 activation. The kinase activity of MYT1 was high during checkpoint activation and reduced during checkpoint recovery. Importantly, although depletion of MYT1 alone did not affect long-term cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models. These results reveal the functions of MYT1 in checkpoint recovery and highlight the potential of MYT1 as a target for anti-cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fung TK, Poon RYC . A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol 2005; 16: 335–342.
Booher RN, Holman PS, Fattaey A . Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997; 272: 22300–22306.
Parker LL, Piwnica-Worms H . Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257: 1955–1957.
van Vugt MA, Bras A, Medema RH . Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 2004; 15: 799–811.
Watanabe N, Arai H, Iwasaki J, Shiina M, Ogata K, Hunter T et al. Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways. Proc Natl Acad Sci USA 2005; 102: 11663–11668.
Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 2004; 101: 4419–4424.
Katayama K, Fujita N, Tsuruo T . Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol 2005; 25: 5725–5737.
Wells NJ, Watanabe N, Tokusumi T, Jiang W, Verdecia MA, Hunter T . The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G(2)/M progression. J Cell Sci 1999; 112: 3361–3371.
Nakajima H, Toyoshima-Morimoto F, Taniguchi E, Nishida E . Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem 2003; 278: 25277–25280.
Stumpff J, Duncan T, Homola E, Campbell SD, Su TT . Drosophila Wee1 kinase regulates Cdk1 and mitotic entry during embryogenesis. Curr Biol 2004; 14: 2143–2148.
Nakajima H, Yonemura S, Murata M, Nakamura N, Piwnica-Worms H, Nishida E . Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit. J Cell Biol 2008; 181: 89–103.
Nakajo N, Yoshitome S, Iwashita J, Iida M, Uto K, Ueno S et al. Absence of Wee1 ensures the meiotic cell cycle in Xenopus oocytes. Genes Dev 2000; 14: 328–338.
Ruiz EJ, Hunt T, Nebreda AR . Meiotic inactivation of Xenopus Myt1 by CDK/XRINGO, but not CDK/cyclin, via site-specific phosphorylation. Mol Cell 2008; 32: 210–220.
Okumura E, Fukuhara T, Yoshida H, Hanada Si S, Kozutsumi R, Mori M et al. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat Cell Biol 2002; 4: 111–116.
Chen Y, Poon RYC . The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 2008; 13: 5016–5029.
Jin P, Gu Y, Morgan DO . Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996; 134: 963–970.
O'Connell MJ, Raleigh JM, Verkade HM, Nurse P . Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16: 545–554.
van Vugt MA, Medema RH . Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24: 2844–2859.
Karlsson-Rosenthal C, Millar JB . Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 16: 285–292.
On KF, Chen Y, Ma HT, Chow JP, Poon RYC . Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther 2011; 10: 784–794.
Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009; 8: 34.
Chow JP, Poon RYC, Ma HT . Inhibitory phosphorylation of cyclin-dependent kinase 1 as a compensatory mechanism for mitosis exit. Mol Cell Biol 2011; 31: 1478–1491.
Krek W, Nigg EA . Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J 1991; 10: 3331–3341.
Wang Y, Decker SJ, Sebolt-Leopold J . Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3: 305–313.
Yam CH, Siu WY, Lau A, Poon RYC . Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J Biol Chem 2000; 275: 3158–3167.
Chan YW, Ma HT, Wong W, Ho CC, On KF, Poon RYC . CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle 2008; 7: 1449–1461.
Chan YW, Chen Y, Poon RYC . Generation of an indestructible cyclin B1 by caspase-6-dependent cleavage during mitotic catastrophe. Oncogene 2009; 28: 170–183.
Siu WY, Arooz T, Poon RYC . Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 1999; 250: 131–141.
Chen Y, Chow JP, Poon RY . Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe. Mol Cancer Res 2012; 10: 626–635.
Liu F, Stanton JJ, Wu Z, Piwnica-Worms H . The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 1997; 17: 571–583.
Ma HT, Tsang YH, Marxer M, Poon RYC . Cyclin A2-cyclin-dependent kinase 2 cooperates with the PLK1-SCFbeta-TrCP1-EMI1-anaphase-promoting complex/cyclosome axis to promote genome reduplication in the absence of mitosis. Mol Cell Biol 2009; 29: 6500–6514.
Chow JP, Siu WY, Ho HT, Ma KH, Ho CC, Poon RYC . Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints. J Biol Chem 2003; 278: 40815–40828.
Chan YW, On KF, Chan WM, Wong W, Siu HO, Hau PM et al. The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint. J Biol Chem 2008; 283: 15716–15723.
Yam CH, Siu WY, Kaganovich D, Ruderman JV, Poon RYC . Cleavage of cyclin A at R70/R71 by the bacterial protease OmpT. Proc Natl Acad Sci USA 2001; 98: 497–501.
Poon RYC, Toyoshima H, Hunter T . Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995; 6: 1197–1213.
Tomayko MM, Reynolds CP . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148–154.
Acknowledgements
We thank Helen Piwnica-Worms and Katsumi Yamashita for generous gifts of reagents. This work was supported in part by grants AOE-MG/M-08/06 and HKU7/CRG/09 to RYCP.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Chow, J., Poon, R. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 32, 4778–4788 (2013). https://doi.org/10.1038/onc.2012.504
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.504
Keywords
This article is cited by
-
Targeting CDK1 in cancer: mechanisms and implications
npj Precision Oncology (2023)
-
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway
Molecular Cancer (2021)
-
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
Leukemia (2020)
-
Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality
Oncogene (2019)
-
Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
Scientific Reports (2017)